Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Efficacy of Aprepitant for Nausea in Patients with Head and Neck Cancer Receiving Daily Cisplatin Therapy

  • Ishimaru, Kotaro (Department of Otolaryngology, Nagasaki University Hospital) ;
  • Takano, Atsushi (Department of Otolaryngology, Nagasaki University Hospital) ;
  • Katsura, Motoyasu (Department of Otolaryngology, Nagasaki University Hospital) ;
  • Yamaguchi, Nimpei (Department of Otolaryngology, Nagasaki University Hospital) ;
  • Kaneko, Ken-ichi (Department of Otolaryngology, Head and Neck Surgery, Nagasaki University Graduate School of Biomedical Sciences) ;
  • Takahashi, Haruo (Department of Otolaryngology, Head and Neck Surgery, Nagasaki University Graduate School of Biomedical Sciences)
  • Published : 2014.12.18
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Although efficacy of aprepitant for suppressing emesis associated with single-dose cisplatin has been demonstrated, there are limited data on the antiemetic effect of this oral neurokinin-1 receptor antagonist during daily administration of cisplatin. Accordingly, we investigated the efficacy and safety of aprepitant in patients with head and neck cancer (HNC) receiving combination therapy with cisplatin and 5-FU (FP therapy). Materials and Methods: Twenty patients with HNC were prospectively studied who received a triple antiemetic regimen comprising granisetron ($40{\mu}g/kg$ on Days 1-4), dexamethasone (8 mg on Days 1-4), and aprepitant (125 mg on day 1 and 80mg on days 2-5) with FP therapy (cisplatin $20mg/m^2$ on days 1-4; 5-FU $400mg/m^2$ on days 1-5) (aprepitant group). We also retrospectively studied another 20 HNC patients who received the same regimen except for aprepitant (control group). Results: For efficacy endpoints based on nausea, the aprepitant group showed significantly better results, including a higher rate of complete response (no vomiting and no salvage therapy) for the acute phase (p=0.0342), although there was no marked difference between the two groups with regard to percentage of patients in whom vomiting was suppressed. There were no clinically relevant adverse reactions to aprepitant. Conclusions: This study suggested that a triple antiemetic regimen containing aprepitant is safe and effective for HNC patients receiving daily cisplatin therapy.

Keywords

References

  1. Albany C, Brames MJ, Fausel C, et al (2012). Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study. J Clin Oncol, 30, 3998-4003. https://doi.org/10.1200/JCO.2011.39.5558
  2. Basch E, Prestrud AA, Hesketh PJ, et al (2011). Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol, 29, 4189-98. https://doi.org/10.1200/JCO.2010.34.4614
  3. Brizel DM, Albers ME, Fisher SR, et al (1998). Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med, 338, 1798-804. https://doi.org/10.1056/NEJM199806183382503
  4. Einhorn LH, Brames MJ, Dreicer R, et al (2007). Palonosetron plus dexamethasone for prevention of chemotherapyinduced nausea and vomiting in patients receiving multipleday cisplatin chemotherapy for germ cell cancer. Support Care Cancer, 15, 1293-300. https://doi.org/10.1007/s00520-007-0255-6
  5. Einhorn LH, Grunberg SM, Rapoport B, Rittenberg C, Feyer P (2011). Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer, 1, 1-4.
  6. Ellebaek E, Herrstedt J (2008). Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy. Curr Opin Support Palliat Care, 2, 28-34. https://doi.org/10.1097/SPC.0b013e3282f44a75
  7. Jordan K, Kinitz I, Voigt W, et al (2009). Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy. Eur J Cancer, 45, 1184-7. https://doi.org/10.1016/j.ejca.2008.11.046
  8. Roila F, Herrstedt J, Aapro M, et al (2010). Guideline update for MASCC and ESMO in the prevention of chemotherapyand radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol, 5, 232-43.
  9. Sun CC, Bodurka DC, Weaver CB, et al (2005). Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer, 13, 219-27. https://doi.org/10.1007/s00520-004-0710-6
  10. Xiao Y, Liu J, Liu YC, et al. (2014). Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Asian Pac J Cancer Prev, 15, 3951-4. https://doi.org/10.7314/APJCP.2014.15.9.3951

Cited by

  1. Influence of dosing times on cisplatin-induced peripheral neuropathy in rats vol.16, pp.1, 2016, https://doi.org/10.1186/s12885-016-2777-0
  2. Neurokinin-1 Receptor Antagonists in Preventing Postoperative Nausea and Vomiting vol.94, pp.19, 2015, https://doi.org/10.1097/MD.0000000000000762
  3. Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapy vol.7, pp.7, 2018, https://doi.org/10.1002/cam4.1560